MX2020013163A - Metodos para tratar trastornos linfoproliferativos malignos. - Google Patents
Metodos para tratar trastornos linfoproliferativos malignos.Info
- Publication number
- MX2020013163A MX2020013163A MX2020013163A MX2020013163A MX2020013163A MX 2020013163 A MX2020013163 A MX 2020013163A MX 2020013163 A MX2020013163 A MX 2020013163A MX 2020013163 A MX2020013163 A MX 2020013163A MX 2020013163 A MX2020013163 A MX 2020013163A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- lymphoproliferative disorders
- treating malignant
- malignant lymphoproliferative
- gsk
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862680739P | 2018-06-05 | 2018-06-05 | |
| PCT/US2019/035576 WO2019236703A1 (en) | 2018-06-05 | 2019-06-05 | Methods of treating malignant lymphoproliferative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020013163A true MX2020013163A (es) | 2021-02-18 |
Family
ID=68769443
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013163A MX2020013163A (es) | 2018-06-05 | 2019-06-05 | Metodos para tratar trastornos linfoproliferativos malignos. |
| MX2024008461A MX2024008461A (es) | 2018-06-05 | 2020-12-03 | Metodos para tratar trastornos linfoproliferativos malignos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024008461A MX2024008461A (es) | 2018-06-05 | 2020-12-03 | Metodos para tratar trastornos linfoproliferativos malignos. |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11510904B2 (https=) |
| EP (1) | EP3801768A4 (https=) |
| JP (2) | JP7794564B2 (https=) |
| KR (1) | KR20210045364A (https=) |
| CN (2) | CN112351819B (https=) |
| AU (1) | AU2019280693B2 (https=) |
| BR (1) | BR112020024931A2 (https=) |
| CA (1) | CA3102555A1 (https=) |
| IL (2) | IL279155B2 (https=) |
| MX (2) | MX2020013163A (https=) |
| WO (1) | WO2019236703A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112351819B (zh) * | 2018-06-05 | 2023-11-10 | 开动疗法公司 | 治疗恶性淋巴增生性疾病的方法 |
| AU2020415440A1 (en) * | 2019-12-26 | 2022-08-04 | Actuate Therapeutics, Inc. | Compounds for the treatment of myelofibrosis |
| WO2022109057A1 (en) * | 2020-11-17 | 2022-05-27 | Brown University | Inhibition of glycogen synthase kinase-3 (gsk-3) |
| JP2022157223A (ja) * | 2021-03-31 | 2022-10-14 | 国立大学法人神戸大学 | 抗ガン剤効果増強剤 |
| CN113684180B (zh) * | 2021-08-31 | 2023-05-26 | 山东大学第二医院 | 一种提高骨髓瘤杀伤活性的nk细胞制备方法 |
| WO2023172629A2 (en) * | 2022-03-08 | 2023-09-14 | Brown University | Anticancer maleimide derivatives for use with immune checkpoint blockade |
| US20250325517A1 (en) * | 2022-06-27 | 2025-10-23 | Actuate Therapeutics, Inc. | Oral dosage forms of elraglusib |
| US20260060969A1 (en) * | 2022-08-04 | 2026-03-05 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of lymphoproliferative disorders |
| WO2025245059A1 (en) * | 2024-05-23 | 2025-11-27 | Yale University | Compositions comprising gsk-3 and/or beta-catenin inhibitors and/or degraders and methods of use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2673368C (en) | 2006-12-19 | 2014-10-28 | The Board Of Trustees Of The University Of Illinois | 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders |
| CA2860250C (en) | 2012-02-21 | 2020-11-10 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
| JP6321662B2 (ja) | 2012-10-12 | 2018-05-09 | ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. | Ｇｓｋ３阻害剤およびその使用の方法 |
| US20160375006A1 (en) * | 2012-10-12 | 2016-12-29 | The Broad Institute, Inc. | Uses of paralog-selective inhibitors of gsk3 kinases |
| WO2014165851A1 (en) * | 2013-04-05 | 2014-10-09 | The Children's Hospital Of Philadelphia | Transient up-regulation of myc in b-cell lymphomas |
| US20170165230A1 (en) | 2014-04-09 | 2017-06-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
| JP6534098B2 (ja) * | 2014-09-12 | 2019-06-26 | 国立大学法人 鹿児島大学 | 成人ｔ細胞白血病治療薬 |
| CN112351819B (zh) * | 2018-06-05 | 2023-11-10 | 开动疗法公司 | 治疗恶性淋巴增生性疾病的方法 |
-
2019
- 2019-06-05 CN CN201980037210.9A patent/CN112351819B/zh active Active
- 2019-06-05 WO PCT/US2019/035576 patent/WO2019236703A1/en not_active Ceased
- 2019-06-05 CN CN202311356900.5A patent/CN117883438A/zh active Pending
- 2019-06-05 US US15/734,699 patent/US11510904B2/en active Active
- 2019-06-05 BR BR112020024931-9A patent/BR112020024931A2/pt not_active Application Discontinuation
- 2019-06-05 IL IL279155A patent/IL279155B2/en unknown
- 2019-06-05 IL IL315565A patent/IL315565A/en unknown
- 2019-06-05 EP EP19815715.8A patent/EP3801768A4/en not_active Withdrawn
- 2019-06-05 AU AU2019280693A patent/AU2019280693B2/en active Active
- 2019-06-05 JP JP2020567578A patent/JP7794564B2/ja active Active
- 2019-06-05 CA CA3102555A patent/CA3102555A1/en active Pending
- 2019-06-05 KR KR1020207037918A patent/KR20210045364A/ko not_active Ceased
- 2019-06-05 MX MX2020013163A patent/MX2020013163A/es unknown
-
2020
- 2020-12-03 MX MX2024008461A patent/MX2024008461A/es unknown
-
2022
- 2022-11-03 US US18/052,369 patent/US11980607B2/en active Active
-
2024
- 2024-03-29 JP JP2024056596A patent/JP2024096738A/ja active Pending
- 2024-04-09 US US18/630,283 patent/US20240366563A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN117883438A (zh) | 2024-04-16 |
| IL315565A (en) | 2024-11-01 |
| CN112351819A (zh) | 2021-02-09 |
| BR112020024931A2 (pt) | 2021-03-09 |
| CN112351819B (zh) | 2023-11-10 |
| IL279155B1 (en) | 2024-10-01 |
| US20240366563A1 (en) | 2024-11-07 |
| MX2024008461A (es) | 2024-07-19 |
| CA3102555A1 (en) | 2019-12-12 |
| US11980607B2 (en) | 2024-05-14 |
| US11510904B2 (en) | 2022-11-29 |
| JP7794564B2 (ja) | 2026-01-06 |
| JP2024096738A (ja) | 2024-07-17 |
| AU2019280693B2 (en) | 2024-10-10 |
| JP2021527039A (ja) | 2021-10-11 |
| US20230126700A1 (en) | 2023-04-27 |
| US20210228546A1 (en) | 2021-07-29 |
| AU2019280693A1 (en) | 2020-12-03 |
| EP3801768A1 (en) | 2021-04-14 |
| WO2019236703A1 (en) | 2019-12-12 |
| EP3801768A4 (en) | 2022-04-20 |
| IL279155B2 (en) | 2025-02-01 |
| IL279155A (en) | 2021-01-31 |
| KR20210045364A (ko) | 2021-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020013163A (es) | Metodos para tratar trastornos linfoproliferativos malignos. | |
| DOP2019000180A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
| DOP2017000271A (es) | Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t | |
| MX379297B (es) | Compuestos alqueno tetrasustituidos y su uso. | |
| CO2017011197A2 (es) | Terapia de combinación fgfr/pd-1 para el tratamiento del cancer | |
| AR102553A1 (es) | Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit | |
| MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
| CL2017000156A1 (es) | Procedimientos para el tratamiento de paramixovirus. | |
| CL2016002516A1 (es) | “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct | |
| PH12021551282A1 (en) | Radioimmunoconjugates and checkpoint inhibitor combination therapy | |
| CR20170014A (es) | Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer | |
| MX2019005402A (es) | Terapias de combinacion del inhibidor de arginasa. | |
| MX2025012087A (es) | Piridazinonas y metodos de uso de estas | |
| MX370664B (es) | Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos. | |
| AR101312A1 (es) | Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton | |
| ECSP21026021A (es) | Moduladores de la expresión de pnpla3 | |
| NI201400111A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
| CO2019011265A2 (es) | Moduladores de la expresión de pcsk9 | |
| MX374749B (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer. | |
| MX387658B (es) | Métodos para tratar y/o prevenir queratosis actínica. | |
| MX2017012123A (es) | Combinaciones de un compuesto inhibidor de fosfoinositido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cancer. | |
| MX2021005876A (es) | Elacestrant en combinacion con abemaciclib en mujeres con cancer de mama. | |
| AR112144A1 (es) | Compuestos para el tratamiento del sarcoma | |
| CO2020010013A2 (es) | Terapia de combinación para tratar o prevenir el cáncer | |
| DOP2013000131A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek |